US Senator Elizabeth Warren has asked the US Federal Trade Commission to "carefully scrutinize" the $16.5 billion bid by Novo Nordisk's (NVO) parent company for contract drug maker Catalent (CTLT) and to block the deal if it's found to be in breach of antitrust rules.
"I am concerned that this deal could increase Novo Nordisk's dominance over vital GLP-1 inhibitor drugs, reducing competition and increasing prices for patients," Warren said in a letter to FTC Chair Lina Khan.
Warren said that Eli Lilly (LLY) -- Novo Nordisk's largest rival in the market for GLP-1 weight loss and diabetes drugs -- "also contracts with Catalent to fill and package its drugs at Catalent sites."
"I am concerned that Novo Nordisk's merger with Catalent will give Novo Nordisk unprecedented visibility into and control over its competitor's production capacity, costs, and business practices, and the ability to preference its own products and obstruct its competitors' use of Catalent to produce GLP-1 drugs," Warren said in the letter.
Novo Nordisk and Catalent didn't immediately respond to requests for comment by MT Newswires.
Price: 117.62, Change: +0.62, Percent Change: +0.53
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。